$2.040
0.000 (0.00%)At close
MURA News
MURA Events
XOMA Completes Acquisition of Entire Share Capital of Mural Oncology
XOMA Royalty (XOMA) completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology (MURA) pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland. Mural shareholders received $2.035 in cash per share. The Acquisition was approved by Mural shareholders at a special meeting of shareholders convened pursuant to section 450(1) of the Irish Companies Act 2014 and an extraordinary general meeting of shareholders held on October 24, 2025. The Irish High Court sanctioned the Scheme on December 3, 2025. On December 5, 2025, the Scheme and the Acquisition became effective upon delivery of the court order to the Irish Companies Registration Office. Prior to the opening of trading on December 5, 2025, all of Mural's shares will cease trading on Nasdaq, and Mural intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.
Mural Oncology Announces Scheme of Arrangement Effective
Mural Oncology (MURA) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 pursuant to which XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation (XOMA) will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025. Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon as practicable following the Effective Date, with DTC participant accounts expected to be credited and the distribution of cheques expected to be complete as soon as practicable. In accordance with the requirements of the Irish Takeover Rules, all consideration paid by Sub to Scheme Shareholders under the terms of the Scheme will be distributed by no later than 19 December 2025.
Mural Oncology Reveals Final Cash Payment Due Upon Acquisition Completion
Mural Oncology (MURA) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (XOMA), XRA 5 Corp. and Mural announced on August 20, the Additional Price Per Share has been finally determined in accordance with Clause 2.4 of the Transaction Agreement as $0.000. As a result, the total cash consideration payable to Mural shareholders on closing of the Acquisition will be $2.035 in cash per share. As previously announced on August 20, 2025, XOMA Royalty, Sub and Mural entered into the Transaction Agreement pursuant to which Sub, a wholly-owned subsidiary of XOMA Royalty, has agreed to acquire the entire issued and to be issued share capital of Mural pursuant to an Irish High Court sanctioned "scheme of arrangement" under Chapter 1 of Part 9 of the Irish Companies Act of 2014. The Acquisition is expected to close in early December 2025, subject to the satisfaction of the outstanding closing conditions and the sanction of the Scheme by the Irish High Court.
Mural Oncology Shareholders Give Green Light to XRA 5 Corp. Acquisition
Mural Oncology (MURA) announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty (XOMA). As described in more detail below, a majority in number of the shareholders of record present and voting, either in person or by proxy and more than 99% of the votes cast at both a scheme meeting of shareholders and an extraordinary general meeting of shareholders, both held on October 24 in Dublin, Ireland, were in favour of the transaction, representing in respect of the Scheme Meeting, approximately 58% of the shares outstanding and eligible to be voted at the Scheme Meeting and in respect of the EGM, approximately 61% of the shares outstanding and eligible to be voted at the EGM.
XRA 5 Corp. to Purchase Mural Oncology for $2.035-$2.24 per Share in Cash
Mural Oncology (MURA) and XOMA Royalty (XOMA) entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty, has agreed to acquire the entire issued and to be issued share capital of Mural for cash subject to the satisfaction of the closing conditions, including approval by Mural Shareholders. Following a strategic review process, the Mural board of directors determined the acquisition and cash offer by XOMA Royalty is in the best interests of all Mural Shareholders and has approved the Acquisition. The Acquisition has also been approved by the boards of directors of XOMA Royalty and Sub. Under the terms of the Acquisition and subject to certain conditions, at closing, each Mural Shareholder would receive a base cash price of $2.035 per share and may receive an additional cash amount per share of up to $0.205 which would be calculated on the basis of the amount by which Mural's Closing Net Cash on the Closing Net Cash Date exceeds its Estimated Closing Net Cash in accordance with the provisions of the transaction agreement entered into between Mural, Sub and XOMA Royalty in respect of the Acquisition. The Base Price Per Share has been calculated on the basis of Mural having approximately $36.2M in Closing Net Cash on the Closing Net Cash Date, and would be payable to Mural Shareholders on closing of the Acquisition regardless of the actual quantum of Mural's Closing Net Cash on the Closing Net Cash Date. The Additional Price Per Share is intended to return any Excess Cash to Mural Shareholders. As a result, the Additional Price Per Share would only be payable to Mural Shareholders on closing of the Acquisition if Mural's Closing Net Cash on the Closing Net Cash Date exceeds the Estimated Closing Net Cash. There is no certainty that Mural's Closing Net Cash on the Closing Net Cash Date will exceed the Estimated Closing Net Cash and, if Mural's Closing Net Cash does not the exceed Estimated Closing Net Cash, the amount of the Additional Price Per Share will be zero and each Mural Shareholder would receive only the Base Price Per Share. The Additional Price Per Share is subject to a cap of a maximum amount of $0.205 per share. The Acquisition, excluding any amount that may be payable in respect of the Additional Price Per Share, values the entire issued and to be issued share capital of Mural at approximately $36.2M. Excluding any Additional Price Per Share which may be payable as described above, the Acquisition represents a: premium of approximately 13.1% to Mural's closing share price of $1.80 on August 19, 2025, being the Business Day immediately before the date on which this Announcement has been released; and premium of approximately 97.6% to Mural's undisturbed closing share price of $1.03 on April 14, 2025. The Mural Directors, who hold Mural Shares representing, in aggregate, approximately 0.42% of Mural's outstanding ordinary shares, Mural RSUs representing, in aggregate, approximately 1.27% of Mural's outstanding ordinary shares and options to acquire Mural Shares representing, in aggregate, approximately 4.32% of Mural's outstanding ordinary shares have entered into irrevocable undertakings to vote in favor of the Acquisition. All outstanding options to acquire Mural Shares held by the Mural Directors have a strike price above the maximum Consideration payable pursuant to the Acquisition and will be cancelled without the right to receive any Consideration in accordance with the terms of the Transaction Agreement. Having taken into account the relevant factors, applicable risks and alternatives available to Mural, the Mural Board, which has been so advised by Lucid Capital Markets, as financial adviser and Rule 3 adviser to Mural, as to the financial terms of the Acquisition, considers the terms of the Acquisition as set out in this Announcement to be fair and reasonable. Accordingly, the Mural Board intends to recommend that Mural Shareholders vote in favor of the Acquisition.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.






